Insights from 2023 ESMO Asia Annual Meeting

 

Insights from 2023 ESMO Asia Annual Meeting
J

ESMO Asia 2023 Summary: "Befotertinib, Osimertinib, Telisotuzumab Vedotin, and MCLA-129 in Locally Advanced/Metastatic NSCLC"

By Insights from 2023 ESMO Asia Annual Meeting FEATURING Junko Tanizaki
By Insights from 2023 ESMO Asia Annual Meeting FEATURING Junko Tanizaki
0 views
February 7, 2024
Comments 0
Login to view comments. Click here to Login
Lung
10:08
Insights from 2023 ESMO Asia Annual Meeting

Oncogene-Driven NSCLC: RET, NTRK, and ROS1

Feat. J. Tanizaki
09:17
Insights from 2023 ESMO Asia Annual Meeting

ESMO Asia 2023 Summary: "Befotertinib, Osimertinib, Telisotuzum…

Feat. J. Tanizaki
06:58
Insights from 2023 ESMO Asia Annual Meeting

ESMO Asia 2023 Insights: "Efficacy & Safety of MCLA-129, an…

Feat. M. Brandão
06:57
Insights from 2023 ESMO Asia Annual Meeting

ESMO Asia 2023 Insights: "TROPION-Lung01 Study - Dato-DXd vs. D…

Feat. M. Ahn
06:45
Insights from 2023 ESMO Asia Annual Meeting

ESMO Asia 2023 Insights: "DeLLphi-301 Study - Tarlatamab for Pa…

Feat. M. Ahn
13:20
Insights from 2023 ESMO Asia Annual Meeting

ESMO Asia 2023 Insights: "EGFR TKIs in NSCLC - Which One, How L…

Feat. M. Tsuboi